profit from every CHF 100 of sales.
CHF 0CHF 100
Bachem
CHF 80.60-0.25% today
+51.2% in 1 year
1-year low CHF 53.301-year high CHF 86.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay CHF 40.59 for every CHF 1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Bachem sold, what it kept, and what it did with the cash.
Sales went from CHF 532 million in 2022 to CHF 695 million in 2025, with CHF 149 million of profit last year.
SalesProfit
Bachem vs. similar companies
Bachem grows the slowest of these 5 and is the most expensive for its profits.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| Bachem | 40.6× · Expensive | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Bachem's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 532 | 577 | 605 | 695 | |
| 171 | 177 | 183 | 200 | |
| 127 | 129 | 133 | 167 | |
| 145 | 162 | 179 | 204 | |
| 101 | 112 | 120 | 149 | |
| 1.37 | 1.50 | 1.60 | 1.98 | |
| 32.2% | 30.7% | 30.2% | 28.7% | |
| 23.9% | 22.4% | 22.0% | 24.1% | |
| 18.9% | 19.4% | 19.9% | 21.4% |
Balance sheet
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,384 | 1,683 | 1,923 | 2,109 |
| Cash | 31 | 158 | 95 | 31 |
| Total debt | 0 | 0 | 0 | – |
| Total liabilities | 214 | 362 | 532 | 650 |
| 1,170 | 1,321 | 1,391 | 1,458 | |
| 74 | 75 | 75 | 75 | |
| 8.1% | 8.0% | 8.3% | 9.1% | |
| 8.6% | 8.5% | 8.6% | 10.2% |
Cash flow
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 93 | 250 | 146 | 272 | |
| 142 | 268 | 285 | 329 | |
| -50 | -19 | -138 | -58 | |
| Dividends paid | 52 | 56 | 60 | 31 |
| 1 | 1 | 1 | 3 | |
| 1 | 1 | 2 | 3 |
Valuation
- 40.6×
- –
- 3.11
- 3.4×
- 8.7×
- –
- 29.4×
- -1.0%
- 2.5%
- 0.5%
Profitability
- 28.7%
- 24.1%
- 21.4%
- –
- 9.1%
- 8.4%
- –
- –
- –
- –
Growth
- +9.3%
- +13.1%
- –
- –
- +0.6%
Financial health
- -0.2×
- –
- –
- 394.0×
- 1.79
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 34%of 952
Top 17%of 883
Bottom 30%of 576
Bottom 43%of 870
Bottom 34%of 985
0.5%of the share price, paid each year
On $1,000 invested$5a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
20.7% of its profit
Room to growStretchedMore than it earnsNews
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
28No pass
Philip Fisher
47No pass
Peter Lynch
32No pass
Joel Greenblatt
7No pass
Charlie Munger
40No pass
Terry Smith
30No pass
Questions about Bachem
Is Bachem a good stock to buy?
A strong, very profitable business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bachem AI analysis
What does Bachem do?
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It is in Biotechnology, based in Bubendorf, Switzerland, with 2,130 employees.
Does Bachem pay a dividend?
Yes. At today's price the dividend is 0.5% a year, about 21% of its yearly profit. In 2025 it paid out CHF 30.7 million in dividends.
How has Bachem stock done over the past year?
Up 51.2% over the past twelve months, to CHF 80.60. It traded between CHF 53.30 and CHF 86.00 and is 6.3% below its high.
Who are Bachem's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Bachem's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.